BrainCells, Inc. Appoints James A. Schoeneck Chief Executive Officer
BrainCells, Inc. (BCI), a privately held, neuroscience-focused, drug development and discovery company targeting novel and /or best-in- class therapies for neuropsychiatric disorders and other central nervous system diseases, announced today the appointment of James A. Schoeneck as Chief Executive Officer and member of the board. Schoeneck, 48, will be responsible for continuing to develop the strategic direction and capabilities of the company.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.